90 related articles for article (PubMed ID: 9329605)
1. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.
Meden H; Mielke S; Marx D; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(4B):3075-7. PubMed ID: 9329605
[TBL] [Abstract][Full Text] [Related]
2. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.
Mielke S; Meden H; Raab T; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(4B):3125-7. PubMed ID: 9329617
[TBL] [Abstract][Full Text] [Related]
3. Effects of pre- and postmenopausal use of exogenous hormones on receptor content in normal human breast tissue: a randomized study.
Hallberg G; Persson I; Naessén T; Magnusson C
Gynecol Endocrinol; 2008 Aug; 24(8):475-80. PubMed ID: 18850387
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.
Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
[TBL] [Abstract][Full Text] [Related]
5. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
6. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status.
Almeida S; Franken N; Zandoná MR; Osório-Wender MC; Hutz MH
Pharmacogenomics J; 2005; 5(1):30-4. PubMed ID: 15381922
[TBL] [Abstract][Full Text] [Related]
8. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies.
Meden H; Mielke S; Schauer A; Kuhn W
In Vivo; 1997; 11(1):51-4. PubMed ID: 9067773
[TBL] [Abstract][Full Text] [Related]
10. Role of ovarian hormones in the regulation of protein metabolism in women: effects of menopausal status and hormone replacement therapy.
Toth MJ; Sites CK; Matthews DE
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E639-46. PubMed ID: 16684855
[TBL] [Abstract][Full Text] [Related]
11. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
12. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
13. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
14. Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age.
Schueller PO; Feuring M; Sharkova Y; Grimm W; Christ M
Int J Cardiol; 2006 Jul; 111(1):42-8. PubMed ID: 16083980
[TBL] [Abstract][Full Text] [Related]
15. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
[TBL] [Abstract][Full Text] [Related]
16. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women.
Thomas T; Burguera B; Melton LJ; Atkinson EJ; O'Fallon WM; Riggs BL; Khosla S
Metabolism; 2000 Oct; 49(10):1278-84. PubMed ID: 11079816
[TBL] [Abstract][Full Text] [Related]
17. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer.
Slattery ML; Potter JD; Curtin K; Edwards S; Ma KN; Anderson K; Schaffer D; Samowitz WS
Cancer Res; 2001 Jan; 61(1):126-30. PubMed ID: 11196149
[TBL] [Abstract][Full Text] [Related]
18. [Can hormonal contraceptives affect plasma levels of IGF-1 and IGFBP-1 in slim women with polycystic ovary syndrome?].
Sindelka G; Cibula D; Fanta M; Kasalová Z; Justová V; Lacinová Z; Skrha J
Cas Lek Cesk; 2001 Aug; 140(15):469-72. PubMed ID: 11569168
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
20. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
